Pharmaceutical nanotechnology has revolutionized drug delivery by enabling controlled, targeted, and sustained release of therapeutic agents, addressing limitations of conventional formulations including poor bioavailability, non-specific distribution, and rapid clearance. This review examines emerging trends in nanocarrier-based drug delivery systems designed to achieve precise spatial and temporal control over drug release kinetics. Key nanotechnological platforms discussed include polymeric nanoparticles, liposomes, solid lipid nanoparticles, dendrimers, metallic nanoparticles, and hybrid nanocarriers, each offering distinct advantages for specific therapeutic applications. Controlled release mechanisms encompass diffusion-mediated, degradation-controlled, and stimuli-responsive strategies, while targeting approaches exploit passive accumulation via enhanced permeability and retention effects and active targeting through ligand-receptor interactions. Sustained release systems provide prolonged therapeutic concentrations, reducing dosing frequency and improving patient compliance. Clinical applications span oncology, infectious diseases, chronic inflammatory conditions, and neurological disorders. Despite significant progress, challenges persist in scalability, manufacturing reproducibility, regulatory approval pathways, and long-term safety assessment. Future directions emphasize personalized nanomedicine, multi-functional nanocarriers integrating diagnostic and therapeutic modalities, and biomimetic systems mimicking natural biological structures. This review provides a comprehensive analysis of current pharmaceutical nanotechnology innovations, critically evaluating their translational potential and identifying research priorities for advancing controlled and targeted drug delivery toward routine clinical implementation.